XAIRs Earnings Show Strong Revenue, Weak Returns

Beyond Air (XAIR) reported fiscal 2026 Q3 results on Feb 13th, 2026, with revenue exceeding expectations but GAAP EPS falling short. The company narrowed its net loss year-over-year while guiding for continued growth amid ongoing financial challenges.

Revenue

Beyond Air’s total revenue surged 104.7% year-over-year to $2.19 million in Q3 2026, driven entirely by its core operations. The segment, which constitutes the company’s sole business line, reported $2.19 million in revenue, reflecting robust adoption of its LungFit PH product in 45+ hospitals.

Earnings/Net Income

The company reduced its per-share loss to $0.85 in Q3 2026 from $2.96 in the prior-year period, a 71.3% improvement. Net losses also contracted to $7.63 million, down 42.8% from $13.33 million. Despite these improvements, Beyond Air has posted losses for five consecutive years in this quarter, underscoring persistent financial pressures. The EPS result, while showing progress, remains a negative outcome for shareholders.

Price Action

XAIR’s stock price declined sharply post-earnings, with an 8.70% weekly drop and a 52.05% monthly decline. The latest trading day saw no intraday movement, reflecting weak investor sentiment.

Post-Earnings Price Action Review

A strategy of purchasing XAIR shares 30 days after earnings releases following three consecutive quarters of revenue growth proved highly ineffective. The approach generated a -72.30% total return over the period, with a -29.92% compound annual growth rate and a -153.27% excess return. The strategy faced a maximum drawdown of 77.20% and a Sharpe ratio of -0.84, highlighting its extreme risk profile and poor risk-adjusted returns.

CEO Commentary

CEO Steven Lisi emphasized a 105% year-over-year revenue increase, driven by high retention rates in hospital clients. He highlighted the NeuroNOS partnership, which includes $32.5M in milestones, and expressed confidence in the Gen II system’s impending FDA approval. Lisi reiterated commitments to disciplined execution and global expansion.

Guidance

The company expects FDA approval for the Gen II system by late 2026 and anticipates a cash runway extending into 2027, supported by $17.8M in cash reserves and recent $4.5M in financing. Management plans to expand Gen I adoption while preparing for the Gen II launch.

Additional News

Beyond Air recently appointed Dan Moorhead as CFO, a strategic move to strengthen financial leadership. The company also secured a $32.5M milestone deal through the NeuroNOS partnership, enhancing its commercial capabilities. Additionally, CEO Steven Lisi outlined plans for the Gen II system’s FDA approval, a critical milestone expected to expand market reach. These developments underscore the company’s focus on innovation and operational discipline.